Economy

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Buckles Under The Trend Lines

Another trade for 3,000 shares valued at $1.35M was sold by BROWN MICHAEL S. $1.35 million worth of stock was sold by STAHL NEIL on Thursday, June 1. Canaccord Genuity's target price suggests a potential upside of 13.02% from the stock's current price.

A number of other equities research analysts have also recently weighed in on the company. Piper Jaffray Companies restated an "overweight" rating and issued a $557.00 price target on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 1st.

Investors and Traders continue to monitor technical levels of shares of Regeneron Pharmaceuticals, Inc. Leerink Swann reiterated a "positive" rating and issued a $552.00 price objective (down previously from $580.00) on shares of Regeneron Pharmaceuticals in a report on Tuesday, August 15th. The mean rating score for this stock is at 1.50. Finally, Vetr cut Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating and set a $419.76 target price for the company.in a research note on Monday, July 11th.

Among 10 analysts covering CDW (NASDAQ:CDW), 6 have Buy rating, 1 Sell and 3 Hold.

As the earnings date approaches, we can see that insider ownership is now 0.40% shares, and institutional ownership is at 72.20% for Regeneron Pharmaceuticals, Inc. In current trading day Smith & Nephew plc (SNN) stock confirmed the flow of -0.91% with the final price of $37.08. Regeneron Pharmaceuticals has a 12-month low of $325.35 and a 12-month high of $565.68.

REGN's insider meaningful buying activity tells us the shares are now in favour, which is fairly consistent with earnings growth expectations, although the share price has not moved significantly to warrant reassessment of mispricing. The company has a market capitalization of $43,570.81, a PE ratio of 38.22, a price-to-earnings-growth ratio of 1.40 and a beta of 1.56. If you are accessing this story on another website, it was illegally copied and republished in violation of United States & worldwide trademark & copyright legislation. Vanguard Group Inc. raised its holdings in shares of Regeneron Pharmaceuticals by 2.9% in the 2nd quarter. The biopharmaceutical company reported $3.13 earnings per share for the quarter, beating the Zacks' consensus estimate of $2.73 by $0.40. It has a return on equity (ROE) of 23.90%.

Revenues rose 23% from previous year to $1.5 billion, also topping analysts' view for $1.45 billion.

Net income increased to $388.3m, or $3.32 a share, from $264.8m, or $2.27 a share, in the same period a year ago. The company's revenue was up 7.3% on a year-over-year basis.

ILLEGAL ACTIVITY WARNING: This news story was originally reported by American Banking News and is owned by of American Banking News.

TRADEMARK VIOLATION WARNING: This story was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. The correct version of this story can be accessed at https://weekherald.com/2017/11/08/regeneron-pharmaceuticals-inc-regn-receives-new-coverage-from-analysts-at-guggenheim.html.

In other news, Director Charles A. Baker sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $450.00, for a total transaction of $956,250.00. Following the sale, the director now owns 11,000 shares of the company's stock, valued at $4,950,000. The purchase was disclosed in a filing with the SEC, which is available at this link. Shares for $710,694 were sold by LEAHY CHRISTINE A. 16,244 CDW Corp (NASDAQ:CDW) shares with value of $994,791 were sold by Richards Thomas E. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company's stock worth $137,000 after buying an additional 28 shares in the last quarter.

Several hedge funds and other institutional investors have recently modified their holdings of REGN. VAGELOS P ROY also sold $4.26 million worth of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) on Thursday, May 25. Jennison Associates now owns 1,922,133 shares of the biopharmaceutical company's stock worth $894,061,000 after buying an additional 189,407 shares in the last quarter. FNY Partners Fund LP increased its holdings in shares of Regeneron Pharmaceuticals by 200.0% during the second quarter. A well-known argument is that insiders investing more in their own companies' shares sends an optimistic signal. Gerstein Fisher now owns 900 shares of the biopharmaceutical company's stock worth $419,000 after buying an additional 195 shares in the last quarter.



Like this

loading...
loading...

Latest


09 November 2017
Enbridge Energy, LP (EEP) Shares Bought by Adams Asset Advisors LLC
The price-to-earnings ratio (P/E) is a valuation method used to compare a company's current share price to its per-share earnings. The ability for Spectra Energy Partners, LP to pay these debts is as follows; current ratio is 0.2 and quick ratio comes to 0.2.

09 November 2017
American Equity Investment Life Holding Company - AEL - Stock Price Today
Apollo Management Holdings L.P. boosted its position in American Equity Investment Life Holding by 26.7% during the 2nd quarter. In addition to RBC Capital reporting its stock price target, a total of 6 brokers have issued a research note on the company.

09 November 2017
Hard Facts About Marathon Oil Corporation (NYSE:MRO)
Shares of Marathon Petroleum Corporation (NYSE: MPC ) have been recently spotted trading 0.53% off of the 52-week high price. Cap Advsr Ltd Limited Com reported 97 shares or 0% of all its holdings. 79 funds opened positions while 205 raised stakes.

09 November 2017
Newborn infant left in 'baby box' at in fire department
OH parents are not asked any questions if they choose to drop an infant off at a hospital police station or fire station. The box is offering parents who cannot care for their newborn an option to give their baby up, no questions asked.

09 November 2017
FY2017 EPS Estimates for The Priceline Group Inc. Increased by Analyst (PCLN)
The stock of Priceline Group Inc (NASDAQ: PCLN ) has "Outperform" rating given on Tuesday, November 7 by RBC Capital Markets. Guggenheim cut shares of The Priceline Group from a "buy" rating to a "neutral" rating in a research note on Tuesday.

09 November 2017
Proshare Advisors Boosted Exxon Mobil (XOM) Position; CSP (CSPI) Sentiment Is 0.5
Horan Securities Inc. purchased a new stake in shares of Exxon Mobil Corp. during the third quarter worth approximately $137,000. Following the completion of the sale, the vice president now owns 231,572 shares in the company, valued at $18,470,182.72.

09 November 2017
Georges St-Pierre submits Michael Bisping to win middleweight belt
He took on 46-year-old Dan Henderson last October - Henderson retired after the fight - and hasn't stepped in the octagon since. He also becomes the fourth multidivisional champion in UFC history; he held the welterweight belt from 2008 to 2013, as well.

09 November 2017
Richard Onyonka re-elected MP for Kitutu Chache South
Onyonka was declared by Constituency Returning Officer Hilda Imbo as the victor of Tuesday's by-election. The constituency's Returning Officer Hilda Imbo declared him victor at 4am Wednesday morning.

09 November 2017
Stocks Movement Analysis: Lululemon Athletica Inc. (LULU), Sucampo Pharmaceuticals, Inc. (SCMP)
IHT Wealth Management LLC boosted its stake in shares of lululemon athletica inc.by 591.0% in the 2nd quarter. (NASDAQ:LULU). Commerzbank Aktiengesellschaft sold 13,918 shares as the company's stock declined 26.14% while stock markets rallied.

09 November 2017
Buick LaCrosse goes upscale with new Avenir version
Buick on Wednesday announced plans to extend availability of its Avenir luxury trim to the 2018 LaCrosse sedan. The Avenir badging spreads into the car's interior, specifically the headrests and sill plates.